INSYS Therapeutics Announces Submission of NDA for Fentanyl SL Spray
PHOENIX--(BUSINESS WIRE)--Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC: NEOL.PK) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for its cancer pain product candidate, Fentanyl SL Spray.